Prognostic value of FHIT, CTNNB1, and MUC1 expression in non--small cell lung cancer

Human Pathology

Volumn 39, Issue 1, 2008, Pages 126-136

  Woenckhaus, Matthias ^a   Merk, Johannes ^b   Stoehr, Robert ^a   Schaeper, Frank ^b   Gaumann, Andreas ^a   Wiebe, Karsten ^a   Hartmann, Arndt ^a   Hofstaedter, Ferdinand ^a   Dietmaier, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Hospital Berlin Buch   (Germany)

Author keywords

Immunohistochemistry; Lung cancer; Prognosis

Indexed keywords

BETA CATENIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FIBROBLAST GROWTH FACTOR RECEPTOR 3; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; MUCIN 1; PROTEIN P53; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; DKK3 GENE; FEMALE; GENE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; POINT MUTATION; PROGNOSIS; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CA-15-3 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 36749058906     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.05.027     Document Type: Article

References (64)

1. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91 (1999) 1194-1210
2. Woenckhaus M., Klein-Hitpass L., Grepmeier U., et al. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol 210 (2006) 192-204
3. Spira A., Beane J., Shah V., et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 101 (2004) 10143-10148
4. Nakabeppu Y., Sakumi K., Sakamoto K., Tsuchimoto D., Tsuzuki T., and Nakatsu Y. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol Chem 387 (2006) 373-379
5. Lan Q., Mumford J.L., Shen M., et al. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25 (2004) 2177-2181
6. Lewis S.J., Cherry N.M., Niven R.M., Barber P.V., and Povey A.C. Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells. Mutat Res 559 (2004) 11-18
7. Sorensen M., Autrup H., Tjonneland A., Overvad K., and Raaschou-Nielsen O. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int J Cancer 110 (2004) 219-224
8. Tews D.S., Nissen A., Kulgen C., and Gaumann A.K. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 50 (2000) 227-237
9. Bagchi D., Bagchi M., Stohs S.J., et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 148 (2000) 187-197
10. Wistuba I.I., Behrens C., Virmani A.K., et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60 (2000) 1949-1960
11. Grepmeier U., Dietmaier W., Merk J., et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int J Oncol 27 (2005) 481-488
12. D'Agostini F., Izzotti A., Balansky R., Zanesi N., Croce C.M., and De Flora S. Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke. Cancer Res 66 (2006) 3936-3941
13. Slattery M.L., Curtin K., Anderson K., et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 92 (2000) 1831-1836
14. Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., and Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61 (1996) 20-26
15. Breuer R.H., Postmus P.E., and Smit E.F. Molecular pathology of non-small-cell lung cancer. Respiration 72 (2005) 313-330
16. Mazieres J., He B., You L., Xu Z., and Jablons D.M. Wnt signaling in lung cancer. Cancer Lett 222 (2005) 1-10
17. Wissmann C., Wild P.J., Kaiser S., et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201 (2003) 204-212
18. Tsuji T., Nozaki I., Miyazaki M., et al. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 289 (2001) 257-263
19. Kobayashi K., Ouchida M., Tsuji T., et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 282 (2002) 151-158
20. Hsieh S.Y., Hsieh P.S., Chiu C.T., and Chen W.Y. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23 (2004) 9183-9189
21. Nozawa N., Hashimoto S., Nakashima Y., et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract 202 (2006) 639-650
22. Poitiers DeW., Lord P.W., Biles B., and Whimster W.F. Bronchial gland histochemistry in lungs removed for cancer. Thorax 35 (1980) 546-551
23. Sozzi G., Sard L., De Gregorio L., et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57 (1997) 2121-2123
24. Kim J.S., Kim H., Shim Y.M., Han J., Park J., and Kim D.H. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 25 (2004) 2165-2171
25. Kim H., Kwon Y.M., Kim J.S., et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 22 (2004) 2363-2370
26. Zochbauer-Muller S., Wistuba I.I., Minna J.D., and Gazdar A.F. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2 (2000) 141-145
27. Feng X., Li L., Gao Y., et al. Fhit protein expression in lung cancer studied by high-throughput tissue microarray. Bull Cancer 94 (2007) E8-E11
28. Zheng H., Tsuneyama K., Takahashi H., et al. Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas. Anticancer Res 27 (2007) 575-581
29. Toledo G., Sola J.J., Lozano M.D., Soria E., and Pardo J. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 17 (2004) 440-448
30. Puglisi F., Minisini A.M., Aprile G., et al. Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. Oncology 63 (2002) 76-83
31. Minami K., Saito Y., Imamura H., and Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38 (2002) 51-57
32. Campling B.G., and el-Deiry W.S. Clinical implications of p53 mutations in lung cancer. Methods Mol Med 75 (2003) 53-77
33. Lau S.K., Weiss L.M., and Chu P.G. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122 (2004) 61-69
34. Awaya H., Takeshima Y., Yamasaki M., and Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 121 (2004) 644-653
35. Retera J.M., Leers M.P., Sulzer M.A., and Theunissen P.H. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol 51 (1998) 891
36. Kase S., Sugio K., Yamazaki K., Okamoto T., Yano T., and Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6 (2000) 4789-4796
37. Zhu C.Q., Shih W., Ling C.H., and Tsao M.S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59 (2006) 790-800
38. van Oers J.M., Lurkin I., van Exsel A.J., et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11 (2005) 7743-7748
39. Burger M., Denzinger S., Hammerschmied C.G., et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med 84 (2006) 833-841
40. Powell C.A., Spira A., Derti A., et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol 29 (2003) 157-162
41. Wilde J., Haenselt V., Luft D., et al. The relationship of histological type and tumor location to prognosis in 1000 patients with lung resection with special reference to adenocarcinoma. Pneumologie 44 (1990) 1287-1293
42. Shah V., Sridhar S., Beane J., Brody J.S., and Spira A. SIEGE: smoking induced epithelial gene expression database. Nucleic Acids Res 33 (2005) D573-D579
43. Sanz-Ortega J., Roig F., Al-Mousa M.M., et al. 17p13 (p53 locus), 5q21 (APC locus) and 9p21 (p16 locus) allelic deletions are frequently found in oral exfoliative cytology cells from smoker patients with non-small-cell lung cancer. Histol Histopathol 22 (2007) 541-545
44. Olapade-Olaopa E.O., Ogunbiyi J.O., MacKay E.H., et al. Further characterization of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multicenter immunohistochemical studies. Appl Immunohistochem Mol Morphol 9 (2001) 261-266
45. Magi-Galluzzi C., Montironi R., Prete E., Kwan P.W., and Delellis R.A. Effect of microwave oven heating times on androgen receptor antigen retrieval from paraffin-embedded prostatic adenocarcinoma. Anticancer Res 16 (1996) 2931-2936
46. Blind C., Koepenik A., Pacyna-Gengelbach M., et al. Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol (2007) [Epub ahead of print]
47. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., and Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006) 1763-1771
48. Bach P.B., Jett J.R., Pastorino U., Tockman M.S., Swensen S.J., and Begg C.B. Computed tomography screening and lung cancer outcomes. JAMA 297 (2007) 953-961
49. Bach P.B., Kelley M.J., Tate R.C., and McCrory D.C. Screening for lung cancer: a review of the current literature. Chest 123 (2003) 72S-82S
50. Read C., Janes S., George J., and Spiro S. Early lung cancer: screening and detection. Prim Care Respir J 15 (2006) 332-336
51. Maeda J., Inoue M., Okumura M., et al. Detection of occult tumor cells in lymph nodes from non-small cell lung cancer patients using reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA with the evaluation of its sensitivity. Lung Cancer 52 (2006) 235-240
52. Minamiya Y., and Ogawa J. The current status of sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Cardiovasc Surg 11 (2005) 67-72
53. Coello M.C., Luketich J.D., Litle V.R., and Godfrey T.E. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 5 (2004) 214-225
54. Wang Y., Zhou Q., Zhang S., et al. Reduction of FHIT gene expression in primary lung cancer: relationship with the proliferation and apoptosis of tumor cell. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 18 (2001) 178-182
55. Wong M.P., Lam W.K., Wang E., et al. Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 62 (2002) 4464-4468
56. Uematsu K., Yoshimura A., Gemma A., et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 61 (2001) 8527-8533
57. Nishizaki M., Sasaki J., Fang B., et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64 (2004) 5745-5752
58. Choi Y.S., Shim Y.M., Kim S.H., et al. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 24 (2003) 441-449
59. Kobayashi K., Ouchida M., Tsuji T., et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 282 (2002) 151-158
60. Jebar A.H., Hurstx A.H., Tomlinson D.C., et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24 (2005) 5218-5225
61. Woenckhaus M., Bubendorf L., Dalquen P., et al. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J Clin Pathol 60 (2007) 483-486
62. Keith W.N., Tan K.B., and Brown R. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes Chromosomes Cancer 4 (1992) 169-175
63. Chen G., Gharib T.G., Huang C.C., et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8 (2002) 2298-2305
64. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346